0
Tarsus Pharmaceuticals, Inc. Banner Image

Tarsus Pharmaceuticals, Inc.

  • Ticker TARS
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Tarsus Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Irvine, California
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVYTM (lotilaner ophthalmic solution) 0.25% is FDA approvedMore in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 for the treatment of Meibomian Gland Disease, which is currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-04 for the potential treatment of Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of activity.
Tarsus Pharmaceuticals, Inc.

Most Recent Annual Report

Tarsus Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Tarsus Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!